Ceptur Therapeutics Overview

  • Founded
  • 2008
Founded
  • Status
  • Private
  • Employees
  • 12
Employees
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $75M
Latest Deal Amount
  • Investors
  • 10

Ceptur Therapeutics General Information

Description

Developer of U1 adaptor technology designed to facilitate the creation of U1 adaptors with therapeutic potential. The company's technology overcomes the limitations of gene silencing technologies, enabling doctors to treat patients with various types of cancers.

Contact Information

Website
cepturtx.com
Formerly Known As
Silagen Incorporated, Silagene, Inc.
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 1 Ilene Court, Building 8
  • Suite 9
  • Hillsborough, NJ 08844
  • United States
+1 (908) 000-0000

Ceptur Therapeutics Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Ceptur Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series A) 19-Jan-2022 $75M 000.00 Completed Generating Revenue
2. Seed Round 13-Aug-2020 00.00 00.00 000.00 Completed Generating Revenue
1. Grant 01-Jan-2010 $189K Completed Generating Revenue
To view Ceptur Therapeutics’s complete valuation and funding history, request access »

Ceptur Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Seed 0,000,000 00.000000 00 00 00 00 00.000
To view Ceptur Therapeutics’s complete cap table history, request access »

Ceptur Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of U1 adaptor technology designed to facilitate the creation of U1 adaptors with therapeutic potential. The co
Biotechnology
Hillsborough, NJ
12 As of 2022
000.00
00000000000 000.00

00000000

ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse c
0000000000000
Durham, NC
00 As of 0000
000.00
00.00 0000-00-00
00000000000 000.00

0000000

ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolo
0000 000000000
Waltham, MA
00 As of 0000
00000
0000 0000-00-00
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ceptur Therapeutics Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
GeneCentric Venture Capital-Backed Durham, NC 00 000.00 00000000000 000.00
0000000 0000000000 Venture Capital-Backed Waltham, MA 00 00000 00000000000 00000
You’re viewing 2 of 2 competitors. Get the full list »

Ceptur Therapeutics Patents

  • 10

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 2

    Granted

  • 2

    Pending

  • 000

    Expiring in next 12 mo

Ceptur Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3134683-A1 Compositions and methods for treating neurodegenerative disorders Pending 26-Mar-2019 00000000000
CA-3132388-A1 Compositions and methods for treating huntington's disease Pending 08-Mar-2019 0000000000
AU-2020238872-A1 Compositions and methods for treating huntington's disease Pending 08-Mar-2019 0000000000
US-9078823-B2 Compositions and methods for gene silencing Active 30-Mar-2007 00000000000 0
US-20150099796-A1 Compositions and methods for gene silencing Granted 30-Mar-2007 C12N15/111
To view Ceptur Therapeutics’s complete patent history, request access »

Ceptur Therapeutics Executive Team (6)

Name Title Board Seat Contact Info
P. Peter Ghoroghchian Ph.D Co-Founder, Chief Executive Officer, Board Member & Co-President
Samuel Gunderson Ph.D Co-Founder, Chief Science Officer & Board Member
Cynthia Davis Chief Financial Officer
Keith-Harrison Dewedoff Interim Chief Financial Officer
Christoph Rosenbohm Ph.D Chief Technology Officer
You’re viewing 5 of 6 executive team members. Get the full list »

Ceptur Therapeutics Board Members (6)

Name Representing Role Since
Aaron Kantoff Ceptur Therapeutics Board Member 000 0000
Aaron Royston MD Self Board Member 000 0000
Colin Walsh Ph.D Self Board Member 000 0000
Daniel Heller Ceptur Therapeutics Board Member 000 0000
James Ballance Ph.D Self Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Ceptur Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ceptur Therapeutics Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Bristol-Myers Squibb Corporation Minority 000 0000 000000 0
Janus Henderson Investors Asset Manager Minority 000 0000 000000 0
Perceptive Advisors Hedge Fund Minority 000 0000 000000 0
Qiming Venture Partners Venture Capital Minority 000 0000 000000 0
venBio Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »

Ready to get started?

Request a free trial